vs
Side-by-side financial comparison of IMAX CORP (IMAX) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $125.2M, roughly 1.0× IMAX CORP). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 35.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 25.8%).
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
IMAX vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $125.2M | $129.7M |
| Net Profit | $637.0K | — |
| Gross Margin | 57.6% | 98.0% |
| Operating Margin | 19.3% | -25.0% |
| Net Margin | 0.5% | — |
| Revenue YoY | 35.1% | 73.4% |
| Net Profit YoY | -88.0% | — |
| EPS (diluted) | $0.02 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $125.2M | $129.7M | ||
| Q3 25 | $106.7M | $164.9M | ||
| Q2 25 | $91.7M | $114.4M | ||
| Q1 25 | $86.7M | $81.7M | ||
| Q4 24 | $92.7M | $74.8M | ||
| Q3 24 | $91.5M | $62.9M | ||
| Q2 24 | $89.0M | $54.1M | ||
| Q1 24 | $79.1M | $41.4M |
| Q4 25 | $637.0K | — | ||
| Q3 25 | $20.7M | $25.7M | ||
| Q2 25 | $11.3M | $-12.8M | ||
| Q1 25 | $2.3M | $-41.2M | ||
| Q4 24 | $5.3M | — | ||
| Q3 24 | $13.9M | $-54.8M | ||
| Q2 24 | $3.6M | $-70.4M | ||
| Q1 24 | $3.3M | $-136.1M |
| Q4 25 | 57.6% | 98.0% | ||
| Q3 25 | 63.1% | 99.0% | ||
| Q2 25 | 58.5% | 98.7% | ||
| Q1 25 | 61.4% | 94.3% | ||
| Q4 24 | 52.2% | 96.6% | ||
| Q3 24 | 55.8% | 97.4% | ||
| Q2 24 | 49.4% | 96.2% | ||
| Q1 24 | 59.3% | 96.4% |
| Q4 25 | 19.3% | -25.0% | ||
| Q3 25 | 27.2% | 15.1% | ||
| Q2 25 | 15.6% | -11.1% | ||
| Q1 25 | 19.3% | -52.2% | ||
| Q4 24 | 10.3% | -81.2% | ||
| Q3 24 | 21.2% | -89.3% | ||
| Q2 24 | 3.2% | -125.1% | ||
| Q1 24 | 15.3% | -336.5% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 19.4% | 15.6% | ||
| Q2 25 | 12.3% | -11.1% | ||
| Q1 25 | 2.7% | -50.4% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 15.2% | -87.1% | ||
| Q2 24 | 4.0% | -130.1% | ||
| Q1 24 | 4.1% | -328.9% |
| Q4 25 | $0.02 | $0.04 | ||
| Q3 25 | $0.37 | $0.28 | ||
| Q2 25 | $0.20 | $-0.14 | ||
| Q1 25 | $0.04 | $-0.47 | ||
| Q4 24 | $0.09 | $-0.71 | ||
| Q3 24 | $0.26 | $-0.70 | ||
| Q2 24 | $0.07 | $-0.91 | ||
| Q1 24 | $0.06 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $151.2M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $337.9M | $114.8M |
| Total Assets | $894.0M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $151.2M | $93.0M | ||
| Q3 25 | $143.1M | $110.9M | ||
| Q2 25 | $109.3M | $75.2M | ||
| Q1 25 | $97.1M | $61.9M | ||
| Q4 24 | $100.6M | $58.5M | ||
| Q3 24 | $104.5M | $36.4M | ||
| Q2 24 | $91.6M | $32.3M | ||
| Q1 24 | $81.0M | $43.3M |
| Q4 25 | $337.9M | $114.8M | ||
| Q3 25 | $349.5M | $73.6M | ||
| Q2 25 | $320.4M | $32.7M | ||
| Q1 25 | $299.5M | $32.8M | ||
| Q4 24 | $299.5M | $59.1M | ||
| Q3 24 | $289.4M | $-30.5M | ||
| Q2 24 | $267.2M | $15.1M | ||
| Q1 24 | $258.8M | $74.1M |
| Q4 25 | $894.0M | $605.2M | ||
| Q3 25 | $889.6M | $538.6M | ||
| Q2 25 | $868.6M | $555.3M | ||
| Q1 25 | $848.3M | $548.8M | ||
| Q4 24 | $830.4M | $594.1M | ||
| Q3 24 | $847.6M | $504.4M | ||
| Q2 24 | $827.4M | $551.1M | ||
| Q1 24 | $824.1M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $29.4M | $60.7M |
| Free Cash FlowOCF − Capex | $28.0M | — |
| FCF MarginFCF / Revenue | 22.3% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | 46.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $118.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.4M | $60.7M | ||
| Q3 25 | $67.5M | $14.3M | ||
| Q2 25 | $23.2M | $5.0M | ||
| Q1 25 | $7.0M | $-42.2M | ||
| Q4 24 | $11.5M | $-35.7M | ||
| Q3 24 | $35.3M | $-42.5M | ||
| Q2 24 | $35.0M | $-40.2M | ||
| Q1 24 | $-11.0M | $-119.0M |
| Q4 25 | $28.0M | — | ||
| Q3 25 | $64.8M | $14.2M | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $5.3M | — | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $34.2M | — | ||
| Q2 24 | $33.5M | $-40.3M | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 22.3% | — | ||
| Q3 25 | 60.7% | 8.6% | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.6% | -74.5% | ||
| Q1 24 | -15.3% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 2.6% | 0.1% | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 1.2% | 0.0% | ||
| Q2 24 | 1.8% | 0.2% | ||
| Q1 24 | 1.4% | 0.0% |
| Q4 25 | 46.11× | — | ||
| Q3 25 | 3.27× | 0.56× | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 2.99× | — | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
